Tammy Tran
Family · Stockbridge, GANPI 1275046617
Payments from drug & device makers
Across 124 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$309
- Exact Sciences$199
- Amgen$167
- Amarin Pharma, Inc.$157
- Lilly USA, LLC$153
- Kowa Pharmaceuticals America, Inc.$130
- plus $955 from 16 others
What the payments were for
- Food & beverage$2,070100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $309 |
| Exact Sciences | 11 | $199 |
| Amgen | 11 | $167 |
| Amarin Pharma, Inc. | 11 | $157 |
| Lilly USA, LLC | 9 | $153 |
| Kowa Pharmaceuticals America, Inc. | 8 | $130 |
| Merck | 8 | $130 |
| Optinose US, Inc. | 8 | $126 |
| GSK | 5 | $98 |
| VBI Vaccine (delaware) Inc. | 5 | $98 |
| Pfizer | 6 | $97 |
| AstraZeneca | 5 | $86 |
| Boehringer Ingelheim | 5 | $76 |
| Gilead | 3 | $58 |
| Abbott | 2 | $39 |
| Lundbeck LLC | 2 | $37 |
| Hikma Pharmaceuticals USA | 2 | $30 |
| Saluda Medical Americas, Inc. | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $17 |
| AbbVie | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
How this compares
$2,070 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 151 | $250,711 |
| TradjentaLinagliptin | 93 | $124,784 |
| JanuviaSitagliptin Phosphate | 66 | $91,540 |
| ProliaDenosumab | 50 | $86,185 |
| VascepaIcosapent Ethyl | 83 | $78,946 |
| Metformin Er GastricMetformin Hcl | 34 | $44,508 |
| RestasisCyclosporine | 25 | $42,321 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $30,367 |
| LinzessLinaclotide | 15 | $22,564 |
| OzempicSemaglutide | 13 | $22,351 |
| FarxigaDapagliflozin Propanediol | 13 | $21,721 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $12,370 |
| Diclofenac Sodium | 105 | $9,343 |
| Omega-3 Acid Ethyl Esters | 45 | $9,240 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $8,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $76 | $375,495244 claims |
| MerckJanuvia, Janumet | $130 | $121,90785 claims |
| AmgenProlia | $167 | $86,18550 claims |
| AbbVieRestasis, Linzess | $15 | $64,88540 claims |
| AstraZenecaFarxiga, Symbicort | $86 | $29,95527 claims |
| Novo NordiskOzempic | $309 | $22,35113 claims |
| GSKBreo Ellipta | $98 | $12,37013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.
Other family in Stockbridge
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.